Prospective, non randomized, Phase II study on MK-3475 in recurrent, platinum-resistant, CPS ≥1 positive ovarian, Fallopian tube and primary peritoneal cancer patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516629-30-00

Acronym

MITO 27

Enrollment

100

Registered

2024-11-11

Start date

2021-06-24

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CPS >1 positive ovarian, Fallopian tube and primary peritoneal cancer patients, platinum-resistant, Recurrent

Brief summary

Overall survival (OS)

Detailed description

Toxicity, Response rate, Progression free survival (PFS), Quality of Life

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival (OS)	—

Secondary

Measure	Time frame
Toxicity, Response rate, Progression free survival (PFS), Quality of Life	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026